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Sacrospinous hysteropexy versus vaginal hysterectomy 
with suspension of the uterosacral ligaments in women with 
uterine prolapse stage 2 or higher: multicentre randomised  
non-inferiority trial
Renée J Detollenaere,1, 2 Jan den Boon,1 Jelle Stekelenburg,3 Joanna IntHout,4 Mark E Vierhout,2 
Kirsten B Kluivers,2 Hugo W F van Eijndhoven1 
ABSTRACT
ObjeCtive
To investigate whether uterus preserving vaginal 
sacrospinous hysteropexy is non-inferior to vaginal 
hysterectomy with suspension of the uterosacral 
ligaments in the surgical treatment of uterine prolapse.
Design
Multicentre randomised controlled non-blinded 
non-inferiority trial.
setting
4 non-university teaching hospitals, the Netherlands.
PartiCiPants
208 healthy women with uterine prolapse stage 2 or 
higher requiring surgery and no history of pelvic floor 
surgery.
interventiOns
Treatment with sacrospinous hysteropexy or vaginal 
hysterectomy with suspension of the uterosacral 
ligaments. The predefined non-inferiority margin was 
an increase in surgical failure rate of 7%.
Main OutCOMe Measures
Primary outcome was recurrent prolapse stage 2 or 
higher of the uterus or vaginal vault (apical 
compartment) evaluated by the pelvic organ prolapse 
quantification system in combination with bothersome 
bulge symptoms or repeat surgery for recurrent apical 
prolapse at 12 months’ follow-up. Secondary outcomes 
were overall anatomical recurrences, including 
recurrent anterior compartment (bladder) and/or 
posterior compartment (bowel) prolapse, functional 
outcome, complications, hospital stay, postoperative 
recovery, and sexual functioning.
results
Sacrospinous hysteropexy was non-inferior for 
anatomical recurrence of the apical compartment with 
bothersome bulge symptoms or repeat surgery (n=0, 
0%) compared with vaginal hysterectomy with 
suspension of the uterosacral ligaments (n=4, 4.0%, 
difference −3.9%, 95% confidence interval for 
difference −8.6% to 0.7%). At 12 months, overall 
anatomical recurrences, functional outcome, quality of 
life, complications, hospital stay, measures on 
postoperative recovery, and sexual functioning did not 
differ between the two groups. Five serious adverse 
events were reported during hospital stay. None was 
considered to be related to the type of surgery.
COnClusiOns
Uterus preservation by sacrospinous hysteropexy was 
non-inferior to vaginal hysterectomy with suspension 
of the uterosacral ligaments for surgical failure of the 
apical compartment at 12 months’ follow-up.
trial registratiOn
Trialregister.nl NTR1866.
Introduction
Pelvic organ prolapse is a common health problem. 
The prevalence of such prolapse is as much as 40% in 
women aged more than 45 years, with millions of 
women affected worldwide, and the incidence is still 
rising as a result of aging populations and increasing 
obesity rates.1 Pelvic organ prolapse has a negative 
influence on women’s quality of life and is associated 
with physical, psychological, and sexual problems.
The lifetime risk for prolapse surgery is 11-20%, and 
worldwide vaginal hysterectomy is the most commonly 
performed surgical procedure for uterine prolapse.2-6 
Performing a hysterectomy for uterine prolapse is not 
an evidence based practice and whether or not the 
uterus should be removed is debatable. Uterus preserv-
ing procedures such as vaginal sacrospinous hys-
teropexy, in which the uterus is attached to the 
sacrospinous ligament, are becoming more popular. In 
a recent study we found a trend towards more uterus 
preservation in the Netherlands, which is in line with 
more women opting to retain their uterus in case of an 
equal outcome with hysterectomy.6-9  Uterus preserva-
tion is thought to be less invasive, and in prospective 
non-randomised and retrospective cohort studies sac-
rospinous hysteropexy was as effective as vaginal 
WhAT IS AlReAdy knoWn on ThIS TopIC
Uterine prolapse is a common health problem, with incidence increasing owing to 
aging populations and rising obesity rates
Vaginal hysterectomy is the standard treatment for uterine prolapse, but uterus 
preservation is gaining popularity
No large randomised trials have compared both treatment options
WhAT ThIS STudy AddS
Sacrospinous hysteropexy was non-inferior to vaginal hysterectomy with 
suspension of the uterosacral ligaments for recurrent prolapse of the apical 
compartment with bothersome bulge symptoms or repeat surgery
After 12 months, overall anatomical outcome, quality of life, subjective outcome, 
hospital stay, recovery, complications, and sexual functioning did not differ 
Women who require surgical correction of uterine prolapse should be given the 
opportunity to choose uterus preservation and avoid hysterectomy
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 hysterectomy, with a similar rate of recurrence and 
repeat surgery but with a shorter operating time, less 
blood loss, faster recovery, and fewer complications.10-12 
A hysterectomy has known benefits as well: it prevents 
the development of uterine cancer and stops menstrual 
bleeding in premenopausal women. After vaginal hys-
terectomy, however, women may be at increased risk of 
recurrent prolapse since hysterectomy disrupts the sup-
portive structures of the pelvic floor.13  To prevent future 
prolapse of the vaginal vault after hysterectomy addi-
tional vault suspension is recommended.14 15  Ran-
domised controlled trials comparing uterus preserving 
techniques and hysterectomy with vault suspension are 
limited. One randomised controlled trial found more 
recurrent uterine prolapse with sacrospinous hys-
teropexy after 12 months, but the recurrence rate was 
only a secondary endpoint.16  Another randomised con-
trolled trial found no differences in sexual functioning 
after six months but did not report on anatomical out-
comes.17
Owing to a lack of well executed randomised con-
trolled trials and clear guidelines on the treatment of 
uterine prolapse, the variation in surgical management 
of uterine prolapse is enormous and a Cochrane 
meta-analysis on surgery for pelvic organ prolapse con-
cluded that more research on this subject is needed.18 
We tested the hypothesis that sacrospinous hysteropexy 
is non-inferior to vaginal hysterectomy with suspension 
of the uterosacral ligaments for surgical failure after 12 
months’ follow-up.
Methods
study design
A detailed version of the trial protocol has been pub-
lished previously.19 In short, all women with uterine 
prolapse at stage 2 or higher (uterine prolapse 1 cm 
above the hymen or beyond) requiring surgery were 
invited to participate. Participants were randomly 
assigned to sacrospinous hysteropexy or vaginal hyster-
ectomy with suspension of the uterosacral ligaments in 
a non-blinded multicentre randomised controlled 
non-inferiority trial.
Women with coexisting prolapse of the anterior or 
posterior vaginal wall, or both were able to participate, 
and cervical elongation together with uterine prolapse 
was no reason for exclusion. Concomitant repair of 
anterior or posterior vaginal prolapse (colporrhaphy) 
was allowed, including anti-incontinence surgery. We 
excluded women with previous pelvic floor or prolapse 
surgery, known malignancy or an abnormal cervical 
smear test result, a wish to preserve fertility, language 
barriers, immunological or haematological disorders 
interfering with recovery after surgery, abnormal ultra-
sound findings of the uterus or ovaries, or abnormal 
uterine bleeding, and those who were unwilling to 
return for follow-up.
All four participating centres were Dutch large 
non-university teaching hospitals. Centres had to offer 
both treatment modalities, and we invited them to par-
ticipate if they were known to perform the interventions 
in the same standardised manner. All gynaecologists 
were experienced and had performed a minimum of 20 
procedures of each intervention before the start of the 
trial. As the participating hospitals were teaching hos-
pitals, residents were allowed to perform procedures 
under direct supervision of the gynaecologist. Gynae-
cologists and residents of the participating centres 
assessed the eligibility of patients. The decision to treat 
uterine prolapse surgically was a shared decision by the 
woman and her gynaecologist.
We gave the women written information and obtained 
informed consent before randomisation. The women 
were randomly allocated in a 1:1 ratio using a web based 
application with computer generated randomisation 
tables in blocks of four, stratified by hospital and stage 
of uterine prolapse. The trial was non-blinded as it was 
impossible to blind surgeons and women to the allo-
cated surgical procedure. An independent doctor who 
was not involved in treatment carried out the 12 month 
follow-up.
Outcome measures
Initially the primary outcome was surgical failure at 
the 12 month follow-up. As outcome definitions to 
evaluate prolapse surgery were improved after the 
start of this trial, we changed the primary outcome 
during enrolment and before data analysis into the 
composite outcome measure of recurrent pelvic organ 
prolapse stage 2 or higher in the apical compartment 
(uterus or vaginal vault) with bothersome bulge symp-
toms or repeat surgery for recurrent apical prolapse at 
the 12 month follow-up. Isala hospital’s medical ethi-
cal committee approved this change, and during 
enrolment we published the protocol in an open 
access online journal.19
We evaluated the original primary outcome, overall 
anatomical failure (pelvic organ prolapse stage 2 or 
higher in any compartment), as a secondary outcome 
together with two additional definitions of surgical fail-
ure or success. Firstly, a composite outcome of success, 
defined as no prolapse beyond the hymen, no bother-
some bulge symptoms, and no repeat surgery or pessary 
use for recurrent prolapse within 12 months. Secondly, 
overall surgical failure: pelvic organ prolapse stage 2 or 
higher, pessary use, or repeat surgery for recurrent pro-
lapse in any compartment within 12 months.20 Other 
secondary outcomes were functional outcome, quality 
of life, complications, hospital stay, postoperative 
recovery, and sexual functioning.
interventions
We referred to a detailed description of the study inter-
ventions to ensure a uniform technique among the sur-
geons.19 All women received perioperative antibiotics, 
prophylaxis against thrombosis, and a bladder catheter 
according to local hospital protocol. Analgesics were 
given postoperatively in accordance with each hospi-
tal’s protocol. The women were advised to abstain from 
heavy physical work for six weeks.
Sacrospinous hysteropexy—Vaginal sacrospinous hys-
teropexy was performed unilaterally to the right sacro-
spinous ligament. The posterior vaginal wall was 
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incised and the sacrospinous ligament accessed 
through the pararectal space. Two permanent sutures 
(Prolene 1.0; Ethicon, Somerville, NJ) were placed 
under direct vision through the sacrospinous ligament 
at least 2 cm from the ischial spine. Additional anterior 
or posterior vaginal wall repair or incontinence surgery 
was performed if indicated. The permanent sutures 
were also placed through the posterior side of the cervix 
and tightened and the uterus redressed. The posterior 
vaginal wall was closed with absorbable sutures (Vicryl 2; 
Ethicon, Somerville, NJ). (Also see www.youtube.com/
watch?v=ySSfy2A1_RM and www.youtube.com/
watch?v=wjct1r37sTw).
Vaginal hysterectomy—The vaginal wall around the 
cervix was circumcised. After bladder and bowel dis-
section the anterior and posterior peritoneum were 
opened. The uterosacral ligaments—strong support-
ive ligaments that attach the cervix to the sacrum—
were identified, ligated, and transected. The uterus 
was released in several steps using clamps and 
sutures. After removal of the uterus, the surgical ped-
icles were inspected for haemostasis and the adnexa 
inspected. The peritoneum was closed using a delayed 
absorbable suture (Vicryl 1.0; Ethicon, Somerville, 
NJ). Additional vault suspension in this study was 
performed by suspension of the uterosacral liga-
ments. Such suspension involves the attachment of 
the uterosacral ligaments to the vaginal vault, thereby 
restoring normal support to the apical compartment.21 
Concomitant anterior or posterior vaginal wall repair 
and anti-incontinence surgery were performed after-
wards if indicated.
Measurements and procedures
Gynaecological examination before surgery included 
pelvic ultrasonography to exclude uterine or ovarian 
disease, a cervical smear test, and vaginal inspection 
in 45° semi-upright position for staging pelvic organ 
prolapse using the pelvic organ prolapse quantifica-
tion system (POP-Q).22  This system involves quantita-
tive measurements of various points of the vaginal 
wall, using the hymen as a reference point. The degree 
of prolapse of the anterior vaginal wall, posterior vag-
inal wall, and uterus or vaginal vault is measured in 
centimetres either above or proximal to the hymen 
(negative number) or beyond, or distal to the hymen 
(positive number), with the plane of the hymen being 
defined as zero. The genital hiatus, perineal body, and 
total vaginal length are also measured. Based on these 
measurements, a stage (0-4) is determined for each 
compartment. The overall stage is equal to the stage of 
the most severely prolapsed compartment. The women 
came to the hospital to be examined for pelvic organ 
prolapse stage at baseline and at six weeks, six 
months, and 12 months after surgery and annually 
thereafter until 60 months’ follow-up. At the time of 
the follow-up visits women completed validated 
health related and disease specific quality of life ques-
tionnaires: short form-36, Euroqol 5D, urogenital dis-
tress inventory, defecatory distress inventory, and 
incontinence impact questionnaire.23-26  We defined 
the presence of bothersome bulge symptoms after sur-
gery as a positive answer to any of the following two 
questions from the urogenital distress inventory: “Do 
you experience a sensation of bulging or protrusion 
from the vagina?” and “Do you have a bulge or some-
thing falling out that you can see in the vagina?” in 
combination with a response “somewhat bothered” to 
“very much bothered” to the question “how much 
does this bother you?” To assess sexual functioning, 
we used the 12 item pelvic organ prolapse/urinary 
incontinence sexual questionnaire, translated from 
the validated questionnaire but not validated for 
Dutch language.27
During hospital admission and the first six weeks 
after surgery, the women kept a diary to evaluate 
postoperative pain (range 0-10), measured by a 
validated visual analogue scale; analgesics; and 
postoperative recovery, measured with the validated 
recovery index-10.28
Data were entered and registered using a web based 
application facilitated by the Dutch consortium for 
studies in women’s health and reproductivity (www.
studies-obsgyn.nl).
statistical analysis
The sample size for this trial was based on the primary 
outcome. Recurrence rates in the apical compartment 
after vaginal hysterectomy vary from 0-12%,29  so that a 
failure rate including bothersome symptoms and repeat 
surgery after sacrospinous hysteropexy of 10% or more 
might be regarded as high. As we expected a failure rate 
of 3% based on outcomes of vaginal hysterectomy in a 
previous randomised study,16 30 we set the non-inferior-
ity margin at 7%. This means that when the upper limit 
of the 95% confidence interval for the estimated differ-
ence in recurrence rate after sacrospinous hysteropexy 
versus vaginal hysterectomy exceeds 7%, sacrospinous 
hysteropexy is inferior to vaginal hysterectomy. Assum-
ing an absolute recurrence rate of 3% in both groups 
and a two sided α risk of 0.05, with two groups of 94 
women each the trial had 80% power with a prespeci-
fied non-inferiority margin of 7% to assess non-inferior-
ity of sacrospinous hysteropexy. Considering a 10% loss 
to follow-up, we required a 208 women—104 in each 
study arm.
We assessed study outcomes by intention to treat 
analysis. In case of missing data on anatomical out-
come at 12 months we applied two strategies. For the 
first by intention to treat analysis, we used the last 
observation carried forward with data at the six month 
follow-up visit if available. If these data were not avail-
able, we left the women out of the intention to treat-last 
observation carried forward analysis. For the second by 
intention to treat analysis we applied conservative 
imputation for all women with missing data at 12 
months (worst case scenario, failure). In the case of 
missing questionnaires, we obtained information on 
the presence or absence of bothersome bulge symptoms 
from the 12 month follow-up visit.
We also carried out a per protocol analysis on the 
 primary and secondary outcomes for anatomical and 
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 surgical failure. This analysis included women who 
completed the entire treatment protocol as originally 
planned, with availability of the pelvic organ prolapse 
quantification scores at 12 months and absence of major 
deviations from the protocol. The Agresti-Coull method 
was used to calculate 95% confidence intervals for 
 differences in proportions.31 For exploratory purposes 
we used Fisher’s exact tests and Mann-Whitney U tests 
to compare proportions and continuous variables 
between the groups. We used paired sample t tests to 
compare mean continuous data within groups. After 
Bonferroni multiple testing adjustment, we considered 
a P value of less than 0.002 to be significant.32 All statis-
tical analyses were performed with SPSS for windows 
(version 22.0.0.1).
Patient involvement
No patients were involved in the design and implemen-
tation of the study, the dissemination of the results, set-
ting the research question or the outcome measures, or 
recruitment.
Results
Between 27 November 2009 and 12 March 2012, 208 
women were randomly assigned to sacrospinous 
 hysteropexy (n=103) or to vaginal hysterectomy (n=105). 
The figure  shows the flow of women through the study. 
Baseline characteristics were similar between the 
groups (table 1 ) and pelvic measurements and charac-
teristics did not differ at baseline (table 2).
Table 3 presents the results on the primary outcome 
and the additional definitions of surgical failure. Sac-
rospinous hysteropexy was non-inferior to vaginal 
hysterectomy for anatomical recurrence of the apical 
compartment with bothersome bulge symptoms or 
repeat surgery for recurrent apical prolapse: sacrospi-
nous hysteropexy 0% (n=0) versus vaginal hysterec-
tomy 4.0% (n=4), difference −3.9% (95% confidence 
interval −8.6% to 0.7%) for the intention to treat-last 
observation carried forward approach. Non-inferiority 
of sacrospinous hysteropexy was also shown in the 
intention to treat analysis with conservative imputa-
tion and the per protocol analysis. The original pri-
mary outcome variable of overall anatomical failure 
occurred in 50% of the women after sacrospinous hys-
teropexy compared with 44% after vaginal hysterec-
tomy (95% confidence interval for difference −7.4% to 
20.1%). No notable differences were found for anatom-
ical recurrences in the different compartments, except 
for the posterior vaginal wall: sacrospinous hys-
teropexy 4% versus vaginal hysterectomy 14% (95% 
confidence interval for difference −18.2% to −1.8%).
Table 4 shows the intraoperative and postoperative 
details of the women, including the secondary out-
comes of complication rate and length of hospital stay. 
Five serious adverse events were reported during hos-
pital stay: two after vaginal hysterectomy and three 
after sacrospinous hysteropexy. One woman devel-
oped  paralytic ileus after vaginal hysterectomy. She 
had also experienced this problem after orthopaedic 
surgery. She aspirated gastric contents eight days after 
surgery, developed aspiration pneumonia, and died 
because of multi-organ failure. The other serious 
adverse events were atrial fibrillation, which required 
cardioversion (vaginal hysterectomy); stroke two days 
after surgery, but with full recovery and no loss of 
function (sacrospinous hysteropexy); postoperative 
pneumonia (sacrospinous hysteropexy); and anaphy-
lactic reaction to prophylactic antibiotics before the 
surgical procedure (sacrospinous hysteropexy); in this 
last woman the  surgical procedure was postponed for 
several months, without any problems. None of the 
serious adverse events were judged to be related to the 
type of surgery.
Tables 5  and 6 provide details on the other secondary 
outcomes. Functional outcome and quality of life did 
not differ significantly between the groups (table 5). 
Postoperative recovery was similar after both interven-
tions, with comparable recovery index-10 scores at 1, 2, 
4, and 6 weeks after surgery (table 6). Among the 
patients who completed the pelvic organ prolapse/uri-
nary incontinence sexual questionnaire before and 
after surgery, there was significant improvement in 
scores in both surgical groups (P<0.002 each) but no 
significant difference in total scores between both 
 interventions (table 6).
Allocated to vaginal hysterectomy (n=105)
  Received vaginal hysterectomy (n=102)
    Received sacrospinous hysteropexy instead
      of vaginal hysterectomy due to technical
      diculties during surgery (n=2)
    Underwent abdominal hysterectomy due to
      adhesions visualised by laparoscopy (n=1)
Allocated to sacrospinous hysteropexy (n=103):
  Received sacrospinous hysteropexy (n=105)
    Received sacrospinous hysteropexy instead
      of vaginal hysterectomy due to technical
      diculties during surgery (n=2)
Discontinued follow-up at 12 months (n=3):
  Lost to follow-up (n=2)
  Deceased (n=1)
Missing POP-Q score (n=4)
Discontinued follow-up at 12 months (n=5):
  Lost to follow-up (n=4)
  Laparoscopic hysterectomy due to endometrial
    cancer (n=1)
Assessed for eligibility (n=389)
Randomised (n=208)
Analysed at baseline (n=105)
Analysed for primary outcome intention to treat
  with last observation carried forward* (n=100)
Analysed for primary outcome intention to treat
  with conservative imputation† (n=105)
Analysed for primary outcome per protocol‡
  (n=90)
Analysed at baseline (n=103)
Analysed for primary outcome intention to treat
  with last observation carried forward* (n=102)
Analysed for primary outcome intention to treat
  with conservative imputation† (n=103)
Analysed for primary outcome per protocol‡
  (n=98)
Excluded (n=181):
  Not meeting inclusion criteria (n=11)
  Declined to participate (n=155)
  Other (n=15)
Flow of women through study. *intention to treat: two patients allocated to vaginal 
hysterectomy (vH) received sacrospinous hysteropexy (sH) and were analysed in the vH 
group. Data at six and 12 month follow up were missing in one patient after sH and six 
patients after vH; one patient after vH had recurrent apical prolapse but pelvic organ 
prolapse quantification (POP-Q) score was missing, this patient was included in the 
intention to treat-last observation carried forward analysis. †Missed data imputed as 
failure. ‡Per protocol analysis: two patients did not receive intended treatment. excluded 
per protocol analysis: lost for follow-up at 12 months (n=8), missing or incomplete POP-Q 
score (n=5), and major protocol deviations (n=9); two patients met two criteria to be 
excluded from per protocol analysis
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Pain scores on the visual analogue scale did not dif-
fer notably between both interventions, except for day 
14 in favour of hysterectomy. In eight out of nine 
women who experienced buttock pain, a typically 
reported problem after sacrospinous hysteropexy, the 
pain resolved (visual analogue scale score <2) sponta-
neously within the first six weeks. One woman under-
went suture cutting and vaginal hysterectomy after 
four months because of persistent pain localised at the 
place of the sacrospinous hysteropexy sutures. After 
this procedure she was free of symptoms.
Fourteen protocol deviations occurred: two women 
received sacrospinous hysteropexy instead of vaginal 
hysterectomy owing to technical difficulties during 
surgery (crossovers). In one woman allocated to vagi-
nal hysterectomy, laparoscopic cystectomy before vag-
inal hysterectomy showed intra-abdominal adhesions, 
and an abdominal hysterectomy was performed. In 
two women an exclusion criterion was ignored before 
randomisation: one woman had had previous pelvic 
floor surgery (repair of posterior vaginal wall pro-
lapse) and another had primary sclerosing cholangitis 
with thrombocytopenia. Three women who were 
assigned to sacrospinous hysteropexy had abnormal 
smear test results and were treated with electro-
surgical excision (n=2) during prolapse surgery or 
 follow-up. In six of 102 women (6%) apical suspension 
after vaginal hysterectomy was performed using a 
McCall procedure instead of suspension of the utero-
sacral ligaments. The other 96 women underwent sus-
pension of the uterosacral ligaments (94%). According 
to the intention to treat principle, we included these 
women in the intention to treat analysis, with all 
women analysed as randomised. In the per protocol 
analysis we excluded these women, except for those 
classed as crossovers (n=2), as the primary outcome 
was related to efficacy and these women had no other 
protocol deviations, and those with abnormal smear 
test results (n=3), as this was regarded as a minor pro-
tocol deviation.
Residents performed three of the procedures in the 
sacrospinous hysteropexy group (3%) and 19 in the 
vaginal hysterectomy group (18%). Overall surgical 
failure rate (recurrent prolapse, pessary use, or repeat 
surgery) did not differ significantly by gynaecologist or 
resident (91 failures out of 180 procedures (50.6%) ver-
sus nine failures out of 19 procedures (47.4%), respec-
tively, P=0.81). Endometrial cancer was diagnosed 
during follow-up in one woman in the sacrospinous 
hysteropexy group (1.0%), and a laparoscopic hyster-
ectomy was performed.
Urinary retention, defined as more than 150 mL urine 
retention after removal of the catheter, was similar 
between the groups (table 4). Affected women received 
a transurethral catheter or were instructed to perform 
clean intermittent self catheterisation. In all women 
spontaneous micturition was achieved after a maxi-
mum length of catheterisation of 40 days (median 5.0 
days, range 1-40 days). Subsequent surgical treatment 
for stress urinary incontinence after 12 months was car-
ried out in 1 of 102 women (1.0%) after sacrospinous 
hysteropexy and 4 of 102 women (3.9%) after vaginal 
hysterectomy (P=0.37).
discussion
Treatment with sacrospinous hysteropexy was non-in-
ferior to vaginal hysterectomy with suspension of the 
uterosacral ligaments for surgical failure of the apical 
compartment in both an intention to treat analysis and 
a per protocol analysis. We found no notable differences 
table 1 | baseline characteristics of women. values are numbers (percentages) unless stated 
otherwise
Characteristics
sacrospinous 
hysteropexy (n=103)
vaginal hysterectomy 
(n=105)
Median (range) age (years) 62.7 (45-85) 61.9 (33-82)
Highest educational level:
 Primary or secondary school 14 (14) 7 (7)
 High school 78 (77) 82 (80)
 Bachelor, master, or academic degree 9 (9) 13 (13)
Comorbidity:
 Cardiovascular disease 39 (38) 32 (31)
 Diabetes mellitus 5 (5) 5 (5)
 Respiratory disease 3 (3) 7 (7)
Current smoker 13 (14) 9 (10)
Median (range) No of vaginal deliveries 2 (0-7) 3 (0-7)
Median (range) No of caesarean deliveries 0 (0-1) 0 (0-2)
Mean (SD) body mass index 26.0 (3.3) 25.9 (3.5)
Percentages were calculated using non-missing data. All patients were analysed as allocated.
table 2 | Pelvic measurements and characteristics at baseline. values are numbers 
(percentages) of women
Characteristics
sacrospinous 
hysteropexy (n=103)
vaginal hysterectomy 
(n=105)
POP-Q stage uterine prolapse (point C)*:
 2 67 (65) 66 (63)
 3 28 (28) 29 (28)
 4 8 (8) 10 (10)
POP-Q stage 2-4:
 Anterior prolapse (Ba ≥−1) 94 (94) 95 (92)
 Posterior prolapse (Bp ≥−1) 29 (29) 33 (32)
Prolapse beyond hymen:
 Apical (POP-Q C >0) 48 (48) 43 (42)
 Anterior (POP-Q Aa or Ba >0) 71 (71) 72 (70)
 Posterior (POP-Q Ap or Bp >0) 11 (11) 11 (11)
Overall POP-Q stage*: n=100 n=103
 2 25 (25) 36 (35)
 3 70 (70) 62 (60)
 4 5 (5) 5 (5)
Vaginal bulge symptoms:
 Any 94/101 (93) 98/103 (95)
 Bothersome 93/100 (93)† 96/101 (95)
POP-Q=pelvic organ prolapse quantification.
Percentages were calculated using non-missing data. All patients were analysed as allocated. Five POP-Q scores 
were missing at baseline.
*System involves quantitative measurements of various points of vaginal wall with hymen as reference point. 
Degree of prolapse of anterior vaginal wall (Aa and Ba), posterior vaginal wall (Ap and Bp), and uterus or vaginal 
vault (C) measured in centimetres both above or proximal to hymen (negative number) or beyond or distal to 
hymen (positive number), with plane of hymen defined as zero. A represents the descent of a measurement point 
3 cm proximal to the hymen on the anterior (Aa) and posterior (Ap) vaginal wall. B is the most descended edge on 
the anterior (Ba) and posterior (Bp) vaginal wall. POP-Q stage 2: most distal prolapse is between 1 cm above and 
1 cm beyond hymen; stage 3: most distal prolapse is prolapsed >1 cm beyond hymen but no further than 2 cm 
less than total vaginal length; stage 4: total prolapse.
†Not all women reported bothersome symptoms at baseline. Questionnaire was provided after women 
consented to participate, therefore amount of bother as reported at outpatient clinic could differ.
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in overall anatomical and surgical failure, functional 
outcome, quality of life, complications, postoperative 
recovery, length of hospital stay, and sexual function-
ing between the interventions. Women who underwent 
sacrospinous hysteropexy reported more buttock pain 
after surgery, but pain scores on the visual analogue 
scale were low and in most cases the pain resolved 
within six weeks.
strengths and limitations of this study
A major strength of this study is its randomised multi-
centre design and sufficient study population. This is to 
our best knowledge the first randomised trial to com-
pare uterus preservation with hysterectomy on a large 
scale using clinically relevant outcome measures.
The study also has some limitations. Firstly, our find-
ings are based on a relatively short follow-up period of 
12 months. However, results from registry studies 
 suggest that the highest risk of prolapse surgery after 
hysterectomy is in the first two postoperative years. Fur-
thermore, not only is long term surgical outcome 
important but also short term secondary outcomes, 
such as complication rate and postoperative recov-
ery.33  34 The women consented to follow-up for 60 
months after surgery, and these data will be further 
analysed.
After vaginal hysterectomy the ligatures of the utero-
sacral ligaments were to be sutured to the vaginal vault 
to aid in long term vaginal support. However, the proto-
col was ignored in six women and the McCall procedure 
was performed instead of suspension of the uterosacral 
ligaments.35  Both procedures rely on the uterosacral 
ligaments for support of the vaginal apex but are con-
sidered different treatment modalities for suspension of 
the vaginal vault, which could have led to differences 
between treatments. As far as we know, strong evidence 
on the best technique for vault suspension after vaginal 
hysterectomy is lacking in the literature, and a recent 
published trial found similar outcomes after suspen-
sion of the uterosacral ligaments and sacrospinous fix-
ation for apical prolapse.36 In the per protocol analysis 
these women were excluded, but this did not alter the 
conclusions.
Another limitation might be that residents were 
allowed to perform sacrospinous hysteropexy or vagi-
nal hysterectomy under direct supervision of a gynae-
cologist because of their training position. Surgery by 
residents may have led to variation in procedures. In the 
hysterectomy group more procedures were performed 
by residents. No statistically significant difference was 
found in surgical failure rate in women who underwent 
surgery by either gynaecologist or resident, but the 
higher number of procedures performed by residents 
could have contributed to a longer operation time in the 
vaginal hysterectomy group. Surgery performed by res-
idents may improve the generalisability of the trial find-
ings as their involvement in treatment of pelvic organ 
prolapse is common in Dutch urogynaecological 
 practice.
Comparison with other studies
The anatomical outcome after sacrospinous hys-
teropexy in our study is in line with that of previous 
studies,16 37  although the only previous randomised 
study showed opposite results: Dietz and colleagues 
found a higher rate of anatomical recurrence of the api-
cal compartment after sacrospinous hysteropexy (7 of 
34 (21%) versus 1 in 31 (3%) after vaginal hysterectomy, 
P=0.03) after 12 months’ follow-up. Possible explana-
tions for this difference might relate to a different surgi-
cal protocol or skills, precise definition of the 
recurrence outcome, and sample size. The primary out-
come in the study reported by Dietz and colleagues was 
recovery time instead of anatomical outcome. These 
authors considered a pelvic organ prolapse stage 2 or 
higher of the uterus or vaginal vault as a recurrence. 
Recurrent prolapse was defined in our study as pro-
lapse of the apical compartment stage 2 or higher (eval-
uated by pelvic organ prolapse quantification system) 
table 3 | Outcomes for pelvic organ prolapse at 12 month follow-up. values are numbers 
(percentages) of women unless stated otherwise
Outcomes
sacrospinous 
hysteropexy
vaginal 
hysterectomy Difference (95% Ci)
Primary outcome*
ITT analysis with LOCF 0/102 (0) 4/100 (4) −3.9 (−8.6 to 0.7)
ITT analysis with conservative 
imputation
6/103 (6) 10/105 (10) −3.6 (−11.2 to 3.9)
Per protocol analysis 0/98 (0) 3/90 (3) −3.3 (−8.0 to 1.3)
Overall surgical failure†
ITT analysis with LOCF 52/102 (51) 49/100 (49) 1.9 (−11.8 to 15.7)
ITT analysis with conservative 
imputation
55/103 (53) 54/105 (51) 1.9 (−11.6 to 15.5)
Per protocol analysis 51/98 (52) 44/90 (49) 3.1 (−11.2 to 17.4)
Composite outcome success‡
ITT analysis with LOCF 91/102 (89) 83/100 (83) 6.1 (−3.6 to 15.8)
ITT analysis with conservative 
imputation
87/103 (84) 82/105 (78) 6.2 (−4.5 to 16.9)
Per protocol analysis 87/98 (89) 75/90 (83) 5.3 (−4.7 to 15.5)
anatomical failure§
Overall anatomical failure: 51/101 (50) 44/100 (44) 6.4 (−7.4 to 20.1)
 Apical compartment 2/102 (2) 7/100 (7) −5.0 (−11.1 to 1.2)
 Anterior compartment 47/101 (47) 33/99 (33) 12.9 (−0.5 to 26.4)
 Posterior compartment 4/101 (4) 14/99 (14) −10.0 (−18.2 to −1.8)
Prolapse beyond hymen¶
Apical (POP-Q C >0) 0/102 (0) 4/100 (4) −3.9 (−8.6 to 0.7)
Anterior (POP-Q Ba >0) 8/101 (8) 6/99 (6) 1.8 (−5.6 to 9.2)
Posterior (POP-Q Bp >0) 0/101 (0) 2/99 (2) −2.0 (−5.9 to 1.9)
repeat surgery¶
Recurrent prolapse 1/102 (1) 4/102 (4) −2.9 (−7.8 to 2.0)
 Apical compartment 0/102 (0) 2/102 (2) −1.9 (−5.7 to 1.8)
 Anterior compartment 1/102 (1) 4/102 (4) −2.9 (−7.8 to 2.0)
 Posterior compartment 0/102 (0) 1/102 (1) −1.0 (−4.2 to 2.3)
Primary surgery different site** 0/102 (0) 3/102 (3) −2.9 (−7.1 to 1.3)
surgery for non-prolapse conditions
Anti-incontinence 1/102 (1) 4/102 (4) −2.9 (−7.8 to 2.0)
Hysterectomy 2/100 (2) — —
ITT=intention to treat; LOCF=last observation carried forward; POP-Q=pelvic organ prolapse quantification. 
Percentages were calculated using non-missing data. Agresti-Coull method used to calculate 95% confidence 
intervals.31
*Recurrent apical prolapse stage ≥2 with bothersome symptoms or repeat surgery for apical prolapse.
†Prolapse POP-Q stage ≥2 (any compartment) or repeat surgery or pessary use.
‡No prolapse beyond hymen, absence of bothersome bulge symptoms, and no repeat surgery or pessary use.
§Prolapse POP-Q stage ≥2.
¶ITT with LOCF.
**Reoperation for pelvic organ prolapse in non-operated compartment.
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in combination with bothersome bulge symptoms or 
repeat surgery for recurrent apical prolapse. In our 
opinion, this composite outcome measure is more clin-
ically relevant than outcome in terms of objective pel-
vic organ prolapse quantification scores alone. Barber 
and colleagues reported on different definitions of suc-
cess after surgery for pelvic organ prolapse in 2009.20 
Treatment success varied widely depending on the 
definition used, but definitions that included the 
absence of vaginal bulge symptoms had the strongest 
relation with the women’s assessment of overall 
improvement and treatment success. Furthermore, the 
authors concluded that the hymen is an important cut-
off point for development of symptoms. As new trials 
probably will use these updated outcome definitions, 
we also analysed our data using the hymen as an ana-
tomical threshold and also used the composite out-
come measure of Barber and colleagues, making this 
trial in the future comparable to that of others.
Although the presence of posterior vaginal wall pro-
lapse in both groups was similar before surgery, more 
repairs of the posterior vaginal wall (colporrhaphies) 
were performed in the vaginal hysterectomy group. 
The surgeons were free to decide on concomitant sur-
gery and in general this was decided during surgery. 
One explanation might be that the surgeons thought 
that the more dorsal axis of the vagina after sacrospi-
nous hysteropexy already protected against a recur-
rent prolapse of the posterior vaginal wall. Despite the 
higher number of posterior colporrhaphies, more 
 anatomical recurrences of the posterior compartment 
occurred after hysterectomy with suspension of the 
uterosacral ligaments, which supports this view. The 
risk for recurrent prolapse of the anterior vaginal wall 
after sacrospinous hysteropexy is often discussed. We 
found no difference in occurrence of prolapse of the 
anterior vaginal wall. This is in line with previous 
studies: a retrospective study by Smilen and col-
leagues found that the occurrence of prolapse of the 
anterior vaginal wall was not altered by sacrospinous 
hysteropexy and the randomised study performed by 
Dietz and colleagues did not find a higher rate of pro-
lapse of the anterior vaginal wall after sacrospinous 
hysteropexy (51%) compared with vaginal hysterec-
tomy (64%) after one year.12  38
Reoperation rates for (recurrent) pelvic organ pro-
lapse did not differ. Two women ended up undergoing 
hysterectomy after uterine preservation. In one woman 
this was because of persistent buttock pain. The overall 
rate of buttock pain after sacrospinous hysteropexy in 
our study (9%) is in line with that of other studies and 
in most women the pain resolved spontaneously.30  Pre-
operative counselling should include information 
about the potential risk of buttock pain. Endometrial 
carcinoma was found in one woman during follow-up 
(1%). A previous retrospective analysis of disease find-
ings after prolapse surgery with hysterectomy showed 
premalignant or malignant abnormalities in 17 of 644 
patients (2.6%).39 In that study, two women (0.3%) had 
endometrial cancer diagnosed. Because of the low inci-
dence and the early diagnosis of endometrial cancer 
owing to blood loss, we believe that future risk of malig-
nancy should not be regarded as a valid reason for 
removal of the uterus.
Clinical implications and future research
Uterus preservation has gained popularity among 
gynaecologists and patients during the past years.6-9 
A recent trial among 213 women from multiple study 
sites throughout the United States found that 36% of 
the women preferred uterus preservation, 20% pre-
ferred hysterectomy, and 44% had no preference, 
assuming equal outcomes after both procedures.7 
Another preference study among 100 women showed 
that 60% would decline hysterectomy if an equally effi-
cacious alternative was available.8 This trial provides 
evidence for sacrospinous hysteropexy being such an 
alternative and therefore this study has important 
implications for clinical practice. Women who want to 
avoid hysterectomy and preserve their uterus can be 
reassured that sacrospinous hysteropexy was equally 
effective as vaginal hysterectomy after short term fol-
low-up. However, longer follow-up is necessary, and 
also randomised controlled trials comparing other 
uterus preserving procedures are needed.
Conclusions
Based on analysis of 12 months’ follow-up, we con-
clude that sacrospinous hysteropexy is non-inferior to 
vaginal hysterectomy with suspension of the uterosa-
cral ligaments for recurrent prolapse of the apical 
table 4 | intraoperative and postoperative details. values are numbers (percentages) of 
women unless stated otherwise
Characteristics
sacrospinous 
hysteropexy 
(n=103)
vaginal 
hysterectomy 
(n=105) Difference (95% Ci)
intraoperative period
Mean (SD) operating time (min) 59 (13) 72 (21) −13.5 (−18.5 to −8.6)
Mean (SD) estimated blood loss (mL) 202 (74) 209 (112) −6.5 (−32.8 to 20.0)
Complications:
 Related to antibiotic use 1 (1) 0 (0) 1.0 (−2.2 to 4.2)
 Related to surgery 0 (0) 1 (1)* −1.0 (−4.2 to 2.2)
Concomitant surgery:
 Anti-incontinence 4 (4) 4 (4) 0.1 (−5.7 to 5.8)
 Anterior colporrhaphy 100 (97) 104 (99) −1.9 (−6.5 to 2.6)
 Posterior colporrhaphy 30 (29) 52 (50) −20 (−33.0 to −7.0)
 Anterior and posterior colporrhaphy 30 (29) 52 (50) −20 (−33.0 to −7.0)
Surgeon:
 Gynaecologist 98 (97) 85 (82) 13.9 (5.1 to 22.7)
 Resident 3 (3) 19 (18) −14.9 (−23.2 to −6.6)
Postoperative period
Mean (SD) length of hospital stay (days) 3 (1) 3 (1) −0.1 (−0.4 to 0.2)
Complications during hospital stay:
 Death 0 (0) 1 (1) −1.0 (−4.2 to 2.2)
 Reoperation because of bleeding 0 (0) 1 (1) −1.0 (−4.2 to 2.2)
 Cerebrovascular accident 1 (1) 0 (0) 1.0 (−2.2 to 4.2)
 Buttock pain 9 (9) 0 (0) 8.6 (2.6 to 14.5)
 Urinary retention 15 (15) 12 (11) 3.1 (−6.2 to 12.4)
 Infection needing antibiotics 3 (3) 0 (0) 2.9 (−1.3 to 7.0)
Endometrial carcinoma 1 (1) 0 (0) 1.0 (−2.2 to 4.2)
Percentages were calculated using non-missing data. All women were analysed as allocated (intention to treat).
*Bowel injury during abdominal hysterectomy.
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 compartment with bothersome bulge symptoms or 
repeat surgery for recurrent apical prolapse. Overall 
anatomical outcome, functional outcome, hospital 
stay, complications, postoperative recovery, and sexual 
functioning did not differ.
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table 5 | Functional outcome and quality of life after sacrospinous hysteropexy and vaginal hysterectomy at 12 month 
follow-up. values are medians (interquartile ranges) of domain scores unless stated otherwise
Domains
before surgery 12 months after surgery
sacrospinous 
hysteropexy (n=101)
vaginal hysterectomy 
(n=104)
sacrospinous 
hysteropexy 
(n=97)
vaginal 
hysterectomy 
(n=99) P value*
Urogenital distress inventory†:
 Overactive bladder 0 (0-44) 22 (0-33) 0 (0-11) 0 (0-11) 0.34
 Urinary incontinence 17 (0-33) 17 (0-33) 0 (0-17) 0 (0-17) 0.11
 Obstructive micturition 8 (0-33) 17 (0-33) 0 (0-0) 0 (0-0) 0.71
 Genital prolapse 50 (33-67) 67 (33-67) 0 (0-0) 0 (0-0) 0.86
 Pain 17 (0-33) 17 (0-33) 0 (0-0) 0 (0-0) 0.86
Defecatory distress inventory†:
 Obstipation 0 (0-17) 0 (0-17) 0 (0-0) 0 (0-0) 0.65
 Obstructive defecation 0 (0-17) 0 (0-10) 0 (0-8) 0 (0-8) 0.85
 Pain 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0.42
 Incontinence 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0.38
 Flatus 33 (0-33) 33 (0-33) 0 (0-33) 33 (0-33) 0.20
Incontinence impact questionnaire‡:
 Mobility 11 (0-33) 11 (0-22) 0 (0-11) 0 (0-11) 0.50
 Physical 0 (0-33) 0 (0-33) 0 (0-0) 0 (0-0) 0.81
 Social 11 (0-22) 0 (0-11) 0 (0-0) 0 (0-0) 0.99
 Embarrassment 0 (0-17) 0 (0-17) 0 (0-0) 0 (0-0) 0.12
 Emotion 0 (0-33) 0 (0-22) 0 (0-0) 0 (0-0) 0.56
Short form-36§:
 Physical functioning 80 (55-90) 80 (65-90) 90 (75-100) 85 (70-95) 0.27
 Social functioning 94 (75-100) 88 (75-100) 100 (88-100) 100 (75-100) 0.20
 Role limitations physical 75 (6-100) 100 (50-100) 100 (100-100) 100 (75-100) 0.89
 Role limitations emotional 100 (75-100) 100 (100-100) 100 (100-100) 100 (100-100) 0.78
 Mental health 84 (72-92) 84 (72-88) 84 (76-92) 84 (72-92) 0.57
 Vitality 70 (50-80) 70 (55-80) 75 (55-80) 75 (65-80) 0.39
 Bodily pain 78 (59-100) 80 (67-100) 100 (67-100) 100 (78-100) 0.92
 General health perception 75 (55-85) 75 (61-85) 75 (60-90) 75 (60-90) 0.72
 Health change 50 (25-50) 50 (50-50) 75 (50-100) 75 (50-100) 0.52
All patients were analysed as allocated.
*P value for exploratory purposes: Mann-Whitney U test of sacrospinous hysteropexy versus vaginal hysterectomy.
†0=no symptoms or not bothersome to 100=most bothersome symptoms.
‡0=best quality of life to 100=worst quality of life.
§0=worst quality of life to 100=best quality of life.
table 6 | Postoperative recovery and sexual functioning after sacrospinous hysteropexy and vaginal hysterectomy at 
12 month follow-up. values are means (standard deviations) unless stated otherwise
time point of assessment
sacrospinous hysteropexy vaginal hysterectomy
P value*no of women Mean (sD) score no of women Mean (sD) score
Recovery index-10†:
 Week 1 99 32 (7) 99 33 (6) 0.66
 Week 2 100 34 (7) 99 34 (7) 0.58
 Week 4 98 36 (7) 98 36 (6) 0.82
 Week 6 98 38 (8) 99 38 (9) 0.87
PISQ-12‡:
 Total score at baseline 56 33 (6) 64 35 (5) 0.05
 Total score at 12 months 49 37 (5)§ 56 37 (4)§ 0.62
PISQ-12=pelvic organ prolapse/urinary incontinence sexual questionnaire.
*P value for exploratory purposes: independent samples t test of sacrospinous hysteropexy versus vaginal hysterectomy.
†10 item questionnaire measuring postoperative recovery on 5 point Likert scale. Summary scale score ranges from 10 to 50, where 50 indicates perfect 
recovery.
‡Total scores range from 0, which represents poorest sexual function, to 48 best sexual function.
§Not shown: paired sample test baseline score and follow-up score (sacrospinous hysteropexy P<0.002 and vaginal hysterectomy P<0.002).
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